PMID- 32590753
OWN - NLM
STAT- MEDLINE
DCOM- 20200708
LR  - 20221005
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 26
DP  - 2020 Jun 26
TI  - The effectiveness and safety of Chinese medicines for the treatment of uveitis: A 
      protocol for systematic review and meta-analysis.
PG  - e20766
LID - 10.1097/MD.0000000000020766 [doi]
LID - e20766
AB  - BACKGROUND: Uveitis is an inflammatory and heterogeneous ocular disorder and has 
      a profound impact on patients' life, work and family. There are substantial costs 
      to the countries and individuals associated with treatment of the complications 
      of uveitis and blindness. Conventional therapies did not lead to satisfactory 
      outcomes for uveitis and are associated with substantial adverse events (AEs). 
      Emerging evidences have proved the important value and potential prospect of 
      Chinese medicines and its compound in uveitis. However, although Chinese 
      medicines are widely used in uveitis, its therapeutic effect and safety are still 
      controversial. It is, therefore, timely to perform an objective and normative 
      systematic review to assess the efficacy and safety of Chinese medicines in 
      treating uveitis on current research. METHODS: The systematic review will include 
      all of the randomized controlled trials (RCT) on the efficacy and safety of 
      Chinese medicines for uveitis. A relevant literature search by sensitive search 
      strategies was conducted using the following electronic databases from their 
      inception to September 30, 2019: PubMed, Web of Science, EMBASE, the Cochrane 
      Library, China National Knowledge Infrastructure (CNKI), Wanfang Database, China 
      Science and Technology Journal database (VIP) and Chinese Biomedical Literature 
      database (CBM). The strategy combines treatment terms and disease: that is, 
      "Medicine, Chinese Traditional" (e.g., "Medicine, Chinese Traditional", TCM, 
      Traditional Chinese medicine, Zhong Yi Xue) and uveitis. We will also search 
      registers of clinical trials, potential gray literature, and conference 
      abstracts. There are no limits on language and publication status. The literature 
      screening, data extraction, and quality assessment will be conducted by 2 
      reviewers independently. The reporting quality and risk of bias will be assessed 
      by other two researchers. Best-corrected visual acuity (BCVA) and improvement in 
      disease activity were assessed as the primary outcome. The secondary outcomes 
      will include laboratory efficacy indexes, score changes in the National Eye 
      Institute Visual Functioning Questionnaire 25 (NEI-VFQ 25), uveitis-related 
      tissue damage or complications, concurrent requirement of corticosteroids, 
      immunosuppressive drugs or biologics, and AEs of treatment. Meta-analysis will be 
      performed using RevMan5.3 software provided by the Cochrane Collaboration. 
      RESULTS: This study will provide a comprehensive review based on current evidence 
      of Chinese medicines treatment for uveitis in several aspects, including BCVA and 
      improvement in disease activity, laboratory efficacy indexes, score changes in 
      the NEI-VFQ 25, uveitis-related tissue damage or complications, etc. CONCLUSION:: 
      The conclusion of this study will provide evidence to determine whether Chinese 
      medicines are an effective and safe intervention for patients with uveitis. 
      ETHICS AND DISSEMINATION: It is not necessary to obtain ethical approval for this 
      study, given that this protocol is for a systematic review. The systematic review 
      will be published in a peer-reviewed journal, presented at conferences and will 
      be shared on social media platforms. PROSPERO REGISTRATION NUMBER: PROSPERO 
      CRD42020153620.
FAU - Han, Mengyu
AU  - Han M
AD  - Beijing University of Chinese Medicine.
AD  - Department of Ophthalmology, China-Japan Friendship Hospital, Beijing.
FAU - Chen, Yang
AU  - Chen Y
AD  - Beijing University of Chinese Medicine.
AD  - Department of Ophthalmology, China-Japan Friendship Hospital, Beijing.
FAU - Nong, Luqi
AU  - Nong L
AD  - Beijing University of Chinese Medicine.
AD  - Department of Ophthalmology, China-Japan Friendship Hospital, Beijing.
FAU - Liu, Ziqiang
AU  - Liu Z
AD  - Beijing University of Chinese Medicine.
AD  - Department of Ophthalmology, China-Japan Friendship Hospital, Beijing.
FAU - Qin, Yali
AU  - Qin Y
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen 
      University, Guangzhou, China.
FAU - Meng, Huan
AU  - Meng H
AD  - Beijing University of Chinese Medicine.
AD  - Department of Ophthalmology, China-Japan Friendship Hospital, Beijing.
FAU - Chen, You
AU  - Chen Y
AD  - Department of Ophthalmology, China-Japan Friendship Hospital, Beijing.
FAU - Wang, Zhijun
AU  - Wang Z
AD  - Department of Ophthalmology, China-Japan Friendship Hospital, Beijing.
FAU - Jin, Ming
AU  - Jin M
AD  - Department of Ophthalmology, China-Japan Friendship Hospital, Beijing.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Humans
MH  - Medicine, Chinese Traditional/*methods
MH  - Meta-Analysis as Topic
MH  - Outcome Assessment, Health Care
MH  - Research Design
MH  - Systematic Reviews as Topic
MH  - Uveitis/*therapy
PMC - PMC7328941
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2020/06/27 06:00
MHDA- 2020/07/09 06:00
PMCR- 2020/06/26
CRDT- 2020/06/27 06:00
PHST- 2020/06/27 06:00 [entrez]
PHST- 2020/06/27 06:00 [pubmed]
PHST- 2020/07/09 06:00 [medline]
PHST- 2020/06/26 00:00 [pmc-release]
AID - 00005792-202006260-00028 [pii]
AID - MD-D-20-04600 [pii]
AID - 10.1097/MD.0000000000020766 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jun 26;99(26):e20766. doi: 
      10.1097/MD.0000000000020766.